Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| EXEL | EXELIXIS, INC. | 2026-07-17 14:59:45 | 55.94 | 0.26 | 0.47 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EXEL | 0000939767 | EXELIXIS, INC. | US30161Q1040 | 254900PJQB59O2O95R37 | 043257395 | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 0101 | DE | 1851 HARBOR BAY PARKWAY | ALAMEDA | CA | 94502 | UNITED STATES | US | 6508377000 | 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502 | 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502 | EXELIXIS INC | Biotechnology | 1994 | Michael M. Morrissey, Ph.D. | 954 | http://exelixis.com | 9,400,000,000 | 253,701,000 | 251,355,083 | Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. | 2026-07-16 15:48:17 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 9,400,000,000 | 4,600,000,000 | 95.8333 | 259,708,689 | -20,172,761 | -7.2076 |
| 2024 | 4,800,000,000 | 100,000,000 | 2.1277 | 279,881,450 | -23,312,809 | -7.6891 |
| 2023 | 4,700,000,000 | -2,131,299,691 | -31.199 | 303,194,259 | -20,893,078 | -6.4467 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Dana T. Aftab, Ph.D. | Executive Vice President | 2025 | 659,058 | 0 | 9,479,940 | 397,250 | 11,000 | 10,547,248 |
| Brenda J. Hefti, J.D. | Senior Vice President, General Counsel | 2025 | 454,545 | 0 | 3,451,975 | 286,751 | 11,000 | 4,204,271 |
| Michael M. Morrissey | Chief Executive Officer, President | 2025 | 1,306,040 | 0 | 30,539,552 | 1,382,591 | 11,000 | 33,239,183 |
| Christopher J. Senner | Chief Financial Officer, Executive Vice President | 2025 | 822,823 | 0 | 9,343,867 | 470,782 | 11,000 | 10,648,472 |
| Jeffrey J. Hessekiel, J.D. | Executive Vice President, General Counsel | 2025 | 672,374 | 0 | 8,309,218 | 0 | 11,000 | 8,992,592 |
| Fiscal Year | Employee Count |
|---|---|
| 2026 | 1,077 |
| 2025 | 1,147 |
| 2023 | 1,310 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 2,320,126,000 | 2,168,701,000 | 1,830,208,000 |
| Cost Of Revenue | 83,697,000 | 76,216,000 | 72,547,000 |
| Gross Profit | 2,236,429,000 | 2,092,485,000 | 1,757,661,000 |
| Research And Development Expenses | 825,001,000 | 910,408,000 | 1,044,071,000 |
| General And Administrative Expenses | 518,727,000 | 492,128,000 | 542,705,000 |
| Operating Expenses | 1,447,935,000 | 1,564,084,000 | 1,659,323,000 |
| Operating Income | 872,191,000 | 604,617,000 | 170,885,000 |
| Net Income | 782,570,000 | 521,267,000 | 207,765,000 |
| Earnings Per Share Basic | 2.88 | 1.8 | 0.65 |
| Earnings Per Share Diluted | 2.78 | 1.76 | 0.65 |
| Weighted Average Shares Outstanding Basic | 271,567,000 | 290,030,000 | 318,151,000 |
| Weighted Average Shares Outstanding Diluted | 281,863,000 | 296,132,000 | 321,464,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 482,488,000 | 217,374,000 | 262,994,000 |
| Marketable Securities Current | 576,603,000 | 893,902,000 | 732,308,000 |
| Accounts Receivable | 286,916,000 | 265,437,000 | 237,407,000 |
| Inventories | 21,686,000 | 22,388,000 | 17,323,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 75,596,000 | 68,478,000 | 67,926,000 |
| Total Assets Current | 1,443,289,000 | 1,467,579,000 | 1,317,958,000 |
| Marketable Securities Non Current | 603,603,000 | 637,291,000 | 728,717,000 |
| Property Plant And Equipment | 98,960,000 | 119,391,000 | 128,731,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 1,401,134,000 | 1,480,111,000 | 1,624,399,000 |
| Total Assets | 2,844,423,000 | 2,947,690,000 | 2,942,357,000 |
| Accounts Payable | 29,623,000 | 38,191,000 | 33,768,000 |
| Deferred Revenue | 1,115,000 | 2,739,000 | 5,406,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 125,382,000 | 95,012,000 | 108,417,000 |
| Total Liabilities Current | 405,644,000 | 403,769,000 | 394,277,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 104,422,000 | 108,895,000 | 94,224,000 |
| Total Liabilities Non Current | 277,460,000 | 299,718,000 | 284,168,000 |
| Total Liabilities | 683,104,000 | 703,487,000 | 678,445,000 |
| Common Stock | 262,000 | 282,000 | 303,000 |
| Retained Earnings | -76,830,000 | -98,647,000 | -173,351,000 |
| Accumulated Other Comprehensive Income | 3,476,000 | -1,347,000 | -3,750,000 |
| Total Shareholders Equity | 2,161,319,000 | 2,244,203,000 | 2,263,912,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 29,055,000 | 28,803,000 | 25,717,000 |
| Share Based Compensation Expense | 112,983,000 | 93,836,000 | 106,345,000 |
| Other Non Cash Income Expense | 11,609,000 | 13,626,000 | 16,797,000 |
| Change In Accounts Receivable | 21,398,000 | 27,950,000 | 22,623,000 |
| Change In Inventories | -12,225,000 | -5,453,000 | 12,977,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | 133,771,000 | -31,079,000 | 29,824,000 |
| Change In Accounts Payable | -50,152,000 | -21,886,000 | 53,246,000 |
| Change In Other Liabilities | 1,899,000 | -149,000 | 1,345,000 |
| Cash From Operating Activities | 884,267,000 | 699,971,000 | 333,324,000 |
| Purchases Of Marketable Securities | 632,497,000 | 927,905,000 | 902,468,000 |
| Sales Of Marketable Securities | 1,022,866,000 | 877,307,000 | 1,038,482,000 |
| Acquisition Of Property Plant And Equipment | 8,429,000 | 28,435,000 | 40,469,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 350,441,000 | -116,783,000 | -26,955,000 |
| Tax Withholding For Share Based Compensation | 71,220,000 | 38,625,000 | 29,122,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 49,154,000 | 61,780,000 | 33,494,000 |
| Repurchase Of Common Stock | 1,159,700,000 | 661,229,000 | 554,870,000 |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -969,594,000 | -628,808,000 | -546,052,000 |
| Change In Cash | 265,114,000 | -45,620,000 | -239,683,000 |
| Cash At End Of Period | 482,488,000 | 217,374,000 | 262,994,000 |
| Income Taxes Paid | 155,296,000 | 170,482,000 | 185,658,000 |
| Interest Paid | — | — | — |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 2.88 | 1.8 | 0.65 |
| Price To Earnings Ratio | 15.1319 | 18.8722 | 36.9077 |
| Earnings Growth Rate | 60 | 176.9231 | 14.0351 |
| Price Earnings To Growth Ratio | 0.2522 | 0.1067 | 2.6297 |
| Book Value Per Share | 7.9587 | 7.7378 | 7.1158 |
| Price To Book Ratio | 5.4758 | 4.3901 | 3.3714 |
| Ebitda | 966,921,000 | 720,552,000 | 419,140,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 8,624,000 | 19,463,000 | 43,824,000 |
| Free Cash Flow | 875,643,000 | 680,508,000 | 289,500,000 |
| Return On Equity | 0.3621 | 0.2323 | 0.0918 |
| One Year Beta | 0.568 | 0.2002 | 0.3988 |
| Three Year Beta | 0.4413 | 0.586 | 0.6831 |
| Five Year Beta | 0.6051 | 0.724 | 0.8069 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Eckhardt Sue Gail | Director | 2026-06-01 | 9,812 | D | 16,079 |
| WYSZOMIERSKI JACK L | Director | 2026-06-01 | 3,925 | D | 284,384 |
| JOHNSON DAVID EDWARD | Director | 2026-05-27 | 19,133 | A | 19,133 |
| POSTE GEORGE | Director | 2026-05-27 | 8,367 | A | 127,199 |
| WYSZOMIERSKI JACK L | Director | 2026-05-27 | 8,367 | A | 288,309 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| LifeSteps Financial, Inc. | 2026-06-30 | 4,353 | 80 | 54.4125 |
| Merit Financial Group, LLC | 2026-06-30 | 4,604,937 | 84,634 | 54.41 |
| Sequoia Financial Advisors, LLC | 2026-06-30 | 1,104,088 | 20,292 | 54.41 |
| Cypress Capital, LLC | 2026-06-30 | 802,058 | 14,741 | 54.41 |
| COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS | 2026-06-30 | 3,274,122 | 60,175 | 54.41 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Horizon Funds | 2026-05-31 | Advisor Class | HSMBX | 52,214 | 2,635,762.72 | 0.3519 |
| Horizon Funds | 2026-05-31 | Investor Class | HSMNX | 52,214 | 2,635,762.72 | 0.3519 |
| Pacer Funds Trust | 2026-04-30 | Pacer US Small Cap Cash Cows ETF | CALF | 829,382 | 36,874,323.72 | 1.0714 |
| Pacer Funds Trust | 2026-04-30 | Pacer Trendpilot US Mid Cap ETF | PTMC | 29,826 | 1,326,063.96 | 0.3378 |
| Pacer Funds Trust | 2026-04-30 | Pacer US Large Cap Cash Cows Growth Leaders ETF | COWG | 616,432 | 27,406,566.72 | 1.2602 |